AKR7A2 is an aldo-keto reductase enzyme that catalyzes NADPH-dependent reduction of aldehydes and serves critical cellular protective functions. The enzyme's primary function includes reducing succinic semialdehyde to gamma-hydroxybutyrate (GHB), a neuromodulator, as demonstrated in human neuroblastoma cells where AKR7A2 knockdown resulted in 90% reduction in SSA reductase activity and significant decrease in intracellular GHB levels 1. AKR7A2 provides cellular protection against oxidative stress by detoxifying reactive aldehydes including 4-hydroxynonenal (HNE), reducing cytotoxicity and DNA damage while maintaining glutathione levels 2. The enzyme is transcriptionally regulated by Nrf2 and functions as part of an adaptive cellular response to oxidative stress 3. Disease relevance includes hepatoprotection, where AKR7A2 protects against atorvastatin-induced hepatotoxicity through Nrf2 activation 4 and ameliorates hepatic fibrosis by inhibiting oxidative stress in hepatic stellate cells 5. Additionally, AKR7A2 expression increases in immune cells following aflatoxin B1 exposure, contributing to detoxification 6. Clinically, AKR7A2 represents a therapeutic target for liver diseases and drug-induced hepatotoxicity, with compounds like 7-hydroxycoumarin showing hepatoprotective effects through AKR7A2 induction 3.